Article content
India has established itself as a major force in the global pharmaceutical landscape, particularly in the biosimilars segment. With a sophisticated regulatory framework overseen by the Central Drugs Standard Control Organisation (CDSCO), India offers both significant opportunities and real challenges for biopharmaceutical developers.
The Indian Regulatory Framework for Biologics
The development and approval of biological medicines in India is governed by:
- The Drugs and Cosmetics Act, 1940 (and subsequent amendments)
- The New Drugs and Clinical Trials Rules, 2019
- CDSCO Guidelines for Similar Biologics (2012, updated)
- WHO guidelines for biotherapeutics (adopted by reference)
The Biosimilars Opportunity
India is uniquely positioned in the global biosimilars market. With a strong manufacturing base, a large patient population, and government support for affordable medicines, Indian biopharma companies are increasingly active in both domestic and global biosimilar development.
Navigating the Regulatory Path
Successfully navigating the Indian regulatory pathway for biologics requires deep understanding of both local requirements and international standards. The convergence of Indian regulations with ICH guidelines is ongoing, creating a dynamic environment that rewards companies with sophisticated regulatory capabilities.
